Protocol Ledger

NCT04908956 · Phase II · TERMINATED

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Interventional Phase II clinical trial protocol NCT04908956 sponsored by ETOP IBCSG Partners Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-04 Enrollment: 6 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04908956
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)6 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04908956
Protocol FieldVerified Registry Value
NCT IdentifierNCT04908956
Consolidated Lead SponsorETOP IBCSG Partners Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment6 participants (ACTUAL)
Registered Start Date2022-08-04
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04908956
Hospital Research SiteLocationSite Profile
Leiden University Medical CenterLeiden, NetherlandsOpen Hospital Dossier ->
National University HospitalSingapore, SingaporeOpen Hospital Dossier ->
National Cancer CenterGoyang-si, South KoreaOpen Hospital Dossier ->
Sahlgrenska University hospitalGothenburg, SwedenOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI